Supplementary Table 1

High throughput identification and characterization of novel, species-selective GPR35 agonists

Zaynab Neetoo-Isseljee, Amanda E. MacKenzie, Craig Southern, Jeff Jerman, Edward G. McIver, Nicholas Harries, Debra L. Taylor and Graeme Milligan.

JPET201798

	pEC_{50}			E_{max} (100μM)		
MRCT code	**Human**	**Mouse**	**Rat**	**Human**	**Mouse**	**Rat**
1007	4.3	<4	5.5	58	42	34
18030	4.8	5.2	6.1	189	135	164
18036	5.9	6.8	6.4	79	82	105
26822	5	4.9	4.8	75	94	41
39029	<4	4.9	5.2	5	67	34
41311	5.2	<4	<4	25	0	1
42475	5.3	4.6	5.1	40	60	60
42699	<4	4.2	5.1	29	103	85
50003	5	<4	<4	19	0	3
50351	4.7	5	<4	71	40	50
54454	7	4.9	5.5	94	62	41
59297	4.8	5.7	6.1	54	66	51
59416	5.5	5.1	4.3	92	74	51
59439	5.1	4.2	5	87	47	86
59521	5.1	<4	<4	61	18	23
59872*	6.8	6.5	5.3	67	60	56
60030	5	<4	<4	68	50	44
60211	5.5	<4	4.2	99	38	46
104124	5.6	<4	<4	98	9	14
121525	5.1	<4	<4	83	6	4
122758	5.3	<4	<4	80	15	29
126907	<4	5.2	5.2	9	39	30
127254	5.3	4.5	<4	44	46	38
132295	5.8	4.8	5	21	29	42
141051	5.1	4.6	4.9	92	82	62
149265	<4	5.4	4	38	23	70
177540	4.5	5.8	4.4	87	76	60
179831	4.6	<4	5.3	103	23	127
192086	<4	5.5	5.8	9	48	10
192973	5.5	5.2	5.2	23	33	44

Supplementary Table 1 The potency and efficacy of a series of compounds repurchased following initial screening of the diversity library against human GPR35 was assessed in BRET-based GPR35-β-arrestin-2 interactions assays using each of the human, rat and mouse orthologs of the receptor. Efficacy values are compared to zaprinast. * One compound was insufficiently soluble to be assayed at 100 μM and therefore efficacy values reflect function at 10 μM. The chemical identity of any of these ligands is available on request.